Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NYXH Stock Forecast 2026-2027
$3.22
Current Price
$139.72M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to NYXH Price Targets
+311.7%
To High Target of $13.26
+213.5%
To Median Target of $10.10
+150.4%
To Low Target of $8.06
NYXH Price Momentum
-4.7%
1 Week Change
+4.5%
1 Month Change
-46.8%
1 Year Change
-30.0%
Year-to-Date Change
-62.7%
From 52W High of $8.64
+16.7%
From 52W Low of $2.76
📊 TOP ANALYST CALLS
Did NYXH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nyxoah is one of their latest high-conviction picks.
Latest NYXH Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, NYXH has a bullish consensus with a median price target of $10.10 (ranging from $8.06 to $13.26). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $3.22, the median forecast implies a 213.5% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NYXH Analyst Ratings
4
Buy
1
Hold
0
Sell
NYXH Price Target Range
Low
$8.06
Average
$10.10
High
$13.26
Current: $3.22
Latest NYXH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NYXH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Stifel | Jonathan Block | Buy | Maintains | $8.00 |
| Mar 23, 2026 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $11.00 |
| Mar 20, 2026 | Stifel | Jonathan Block | Buy | Maintains | $10.00 |
| Jan 29, 2026 | Stifel | Jonathan Block | Buy | Maintains | $11.00 |
| Nov 14, 2025 | Piper Sandler | Adam Maeder | Overweight | Reiterates | $9.00 |
| Apr 21, 2025 | Stifel | Jonathan Block | Buy | Maintains | $14.00 |
| Apr 8, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $15.00 |
| Mar 26, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $15.00 |
| Mar 14, 2025 | Stifel | Jonathan Block | Buy | Maintains | $15.00 |
| Dec 13, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $17.00 |
| Nov 5, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $16.00 |
| Oct 11, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $17.00 |
| Sep 30, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Aug 7, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $13.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $18.00 |
| Aug 7, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $16.00 |
| Jun 24, 2024 | Stifel | Jonathan Block | Buy | Maintains | $19.00 |
| May 24, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $18.00 |
| May 15, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Maintains | $17.00 |
| May 15, 2024 | Oppenheimer | Suraj Kalia | Outperform | Maintains | $15.00 |
Nyxoah SA (NYXH) Competitors
The following stocks are similar to Nyxoah based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nyxoah SA (NYXH) Financial Data
Nyxoah SA has a market capitalization of $139.72M with a P/E ratio of -1.4x. The company generates $11.81M in trailing twelve-month revenue with a 63.1% profit margin.
Revenue growth is +346.9% quarter-over-quarter, while maintaining an operating margin of -329.3% and return on equity of -111.0%.
Valuation Metrics
Market Cap
$139.72M
Enterprise Value
$159.22M
P/E Ratio
-1.4x
PEG Ratio
-0.1x
Price/Sales
14.1x
Growth & Margins
Revenue Growth (YoY)
+346.9%
Gross Margin
+64.2%
Operating Margin
-329.3%
Net Margin
+63.1%
EPS Growth
+346.9%
Financial Health
Cash/Price Ratio
+34.1%
Current Ratio
1.3x
Debt/Equity
85.6x
ROE
-111.0%
ROA
-37.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nyxoah SA (NYXH) Business Model
About Nyxoah SA
What They Do
Develops innovative solutions for sleep apnea treatment.
Business Model
Nyxoah SA generates revenue through the commercialization of its Genio system, a minimally invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company focuses on expanding its market presence globally, especially after obtaining FDA approval for the U.S. market, and engages in strategic initiatives including manufacturing expansions and surgeon training programs to support its sales efforts.
Additional Information
Founded in 2009 and based in Mont-Saint-Guibert, Belgium, Nyxoah SA employs around 184 individuals and is committed to addressing the growing demand for effective sleep disorder treatments. The company is positioned to capitalize on the rising prevalence of obstructive sleep apnea, making advancements in neuromodulation therapies a crucial part of its strategy.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
183
CEO
Mr. Olivier Taelman
Country
Belgium
IPO Year
2021
Website
www.nyxoah.comNyxoah SA (NYXH) Latest News & Analysis
Latest News
Quick Summary
Nyxoah SA (NYXH) held its Q4 2025 earnings call, discussing financial performance and future outlook. Key details include revenue figures and strategic initiatives.
Why It Matters
Nyxoah SA's Q4 2025 earnings call provides insights into its financial performance and future outlook, which can influence stock valuation and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Nyxoah reported Q4 2025 revenue of €6.3M, a 347% YoY increase, and full-year revenue of €11.0M, up 122%. The U.S. commercialization is strong, with 145 surgeons trained. Cash reserves stand at €48.0M.
Why It Matters
Nyxoah's strong revenue growth and U.S. commercialization success signal increased market demand for its OSA solutions, potentially enhancing investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nyxoah SA reported a quarterly loss of $0.68 per share, worse than the estimated loss of $0.65, and a decline from a loss of $0.49 per share in the same quarter last year.
Why It Matters
Nyxoah's larger-than-expected quarterly loss raises concerns about its financial performance and operational efficiency, potentially impacting investor confidence and stock valuation.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Nyxoah SA received a transparency notification from Robert Taub and Robelga SRL, indicating Robelga SRL crossed the 3% shareholding threshold as of December 30, 2025.
Why It Matters
The notification indicates a significant change in shareholding, with Robelga SRL surpassing the 3% threshold, potentially affecting stock control and investor sentiment towards Nyxoah SA.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nyxoah SA received a transparency notification from BNP Paribas Asset Management on March 11, 2026, as per Belgian law on large shareholdings disclosure.
Why It Matters
Transparency notifications indicate changes in shareholding, which can impact stock price and investor sentiment. Monitoring such shifts helps assess market dynamics and institutional confidence in Nyxoah.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference
1 month ago
Quick Summary
Nyxoah will participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference, presenting opportunities for investor engagement and insights into its business.
Why It Matters
Nyxoah's participation in a major healthcare conference highlights its visibility and potential for investor interest, which could influence stock performance and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About NYXH Stock
What is Nyxoah SA's (NYXH) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Nyxoah SA (NYXH) has a median price target of $10.10. The highest price target is $13.26 and the lowest is $8.06.
Is NYXH stock a good investment in 2026?
According to current analyst ratings, NYXH has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NYXH stock?
Wall Street analysts predict NYXH stock could reach $10.10 in the next 12 months. This represents a 213.5% increase from the current price of $3.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nyxoah SA's business model?
Nyxoah SA generates revenue through the commercialization of its Genio system, a minimally invasive hypoglossal neurostimulation therapy for obstructive sleep apnea. The company focuses on expanding its market presence globally, especially after obtaining FDA approval for the U.S. market, and engages in strategic initiatives including manufacturing expansions and surgeon training programs to support its sales efforts.
What is the highest forecasted price for NYXH Nyxoah SA?
The highest price target for NYXH is $13.26 from at , which represents a 311.7% increase from the current price of $3.22.
What is the lowest forecasted price for NYXH Nyxoah SA?
The lowest price target for NYXH is $8.06 from at , which represents a 150.4% increase from the current price of $3.22.
What is the overall NYXH consensus from analysts for Nyxoah SA?
The overall analyst consensus for NYXH is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $10.10.
How accurate are NYXH stock price projections?
Stock price projections, including those for Nyxoah SA, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 11:03 AM UTC